IL17A and systemic sclerosis: One of the advantages of this study is the ability to analyse the effect of IL-17A on SSc patient-derived DVSMCs, which shows that IL-17A derived from the serum of SSc patients has the capability of enhancing proliferation, collagen synthesis and secretion, and migration.